"Good medicine" to grab the 10 billion diabetes market, Haussen heavy-weight imitation of the evaluation; the domestic 1.9 billion class of "anticoagulant fighter - Delava Shaban", is day and day again approved; Huarun Seco, Lizhu....

Guide: Good medicine to see a week of consistency evaluation! Up to now, CDE has received a total of 2269 acceptance numbers (534 varieties of 590 enterprises, according to supplementary applications, the same below), of which 641 acceptance numbers have been evaluated.
this week (August 1 to August 7), five more varieties were unanimously evaluated and 14 varieties were hosted.
review edified the details of 5 varieties, Howson first imitation approved this week there are 5 varieties through consistency evaluation, are the new drug registration classification 4 categories approved production, as passed;
of which Haussen's Engree net tablet is the first approved, and is considered to pass a consistency evaluation, the details are as follows: This week's consistency evaluation of the details of the Engrenet Engre net belongs to the sodium-glucose synergetic transport protein-2 (SGLT-2) inhibitor class of drugs, used in conjunction with diet control and exercise, to improve blood sugar control in patients with type 2 diabetes.
Engrenet was jointly developed by Bollinger Ingham and Lilly, was approved by the U.S. FDA in August 2014 and imported in China in 2017.
is understood to be one of the world's best-selling drugs, TOP40, with Engler's net global sales of $3.354 billion, according to Bollinger Ingham and Lilly's 2019 earnings.
Engrenet 2019 after national negotiations, included in the health insurance Category B list, according to the drug intelligence winning bid database shows that the current Engrenet net film the latest winning bid of 4.24 yuan / tablet (10 mg), compared to the pre-health insurance negotiations (9.75 yuan / tablet) price reduction of 56.5 percent.
according to the drug registration and acceptance database shows that up to now a total of 6 enterprises reported production, is now the leading pharmaceutical industry, successfully won the first imitation, and as with the consistency of evaluation, to grab the original research in the Chinese market is imperative.
Engrenet net film details table atorvastatin calcium tablets atorvastatincalcium for his statin lipid conditioning drug.
is suitable for hesym family or non-cogan hypercholesterolemia and mixed hyperlipidemia, as well as pure hematophilion hypercholesterolemia.
it is understood that Atorvastatin is the world's first super-heavy species with annual sales of more than $10 billion.
according to the sales database of pharmaceutical hospitals, in 2019 the domestic sample hospital Atorvastatin calcium tablet sales of 1.691 billion yuan, of which the original Research Pfizer accounted for the largest share of 82.38 percent, followed by Jialin Pharmaceuticals 17.42 percent.
worth mentioning is that the Atorvastatin calcium tablets are the "4 plus 7" collection varieties, and The Artorvastatin calcium tablets of Jialin Pharmaceuticals were selected at a low price of 6.6 yuan with 20mg x 7 tablets.
so far, a total of 8 enterprises have been rated, of which 6 enterprises have been rated.
Atovastatin calcium tablet consistency evaluation details Monrust sodium chewing tablet Sodium Monrust sodium chewing tabletist is a powerful, selective white triene receptor antagonist, suitable for the prevention and long-term treatment of asthma in children between 2 and 14 years of age, as well as to reduce the symptoms caused by allergic rhinitis.
first listed in the European Union in 1997, approved by the FDA in 1998 and listed in China in 1999.
Mengrustss sodium chewing tablets in 2019 domestic sample hospital sales reached 122 million yuan, of which the original research accounted for 70.71 percent, Sichuan Otsuka Pharmaceuticals accounted for 16.83 percent, followed by LunanBat accounted for 12.12 percent.
according to pharmaceutical data, the current domestic Menglust sodium chewing tablet market approval has 11, involving 8 manufacturers, of which 6 enterprises through the consistency evaluation, are as if passed, and included in China's listed drug catalog set.
Munruster sodium chewing tablet consistency evaluation table Viglitin tablet vigretin is an efficient selective dipeptide peptidease-4 (DPP-4) inhibitor.
is used to treat type 2 diabetes, formerly known as Novartis.
According to pharmaceutical data, the current domestic Vigretin tablet sin chip enterprises have a total of 6, Haussen, Qilu Pharmaceuticals, Beijing Ted Pharmaceuticals, Nanjing Sanhe Pharmaceuticals, Nanjing Yuke Pharmaceuticals, as well as this week's approval of China Resources Seco.
and are treated as consistent evaluations.
delavaban tablet Levasaban is a new type of oral anticoagulant used in the prevention and treatment of venous thromboembolism disease, as well as the stroke prevention of non-valve atrial fibrillation.
jointly developed by Bayer/Johnson, was first approved by the European Union in September 2008 and approved for listing in China in March 2009.
public data show that in 2019, Dewar Saban's global sales exceeded $6.9 billion.
public data show that in China, The sales of 2018 sales of nearly 1.9 billion yuan, all from the original research enterprises. the main reason for the
is that the earliest approval time for domestic genericdrugs is August 2019, so far, only 4 enterprises have been approved for listing, and in accordance with the relevant policy provisions, all through the consistency evaluation.
delavata saban film domestic details form declaration acceptance of 14 varieties were accepted, clinical shortage of drug first declaration this week CDE new consistency evaluation acceptance number 20 (14 varieties), of which 9 for injections, Zhengda Tianqing, Lizhu Pharmaceuticals, Luoxin Pharmaceuticals have re-reported the consistency evaluation of heavy injections, in addition, it is worth mentioning that the clinical shortage of drugs first declared to be accepted for the Shanghai XudongHai Pharmaceuticals.
this week's consistency evaluation declaration acceptance details of fluorosterol injection seroroquinol belongs to the classic first generation of antipsychotic drugs, used in acute and chronic schizophrenia, mania.
February 11, 1958, fluorools were developed by Dr. Paul.A. Janssen's team and were approved by the U.S. FDA for listing in 1967.
1985, Dr. Paul Jansen of Belgium, Youngson Pharmaceuticals of Belgium, established Xi'an Jansen PharmaceuticalCo., a joint venture with China.
currently only domestic enterprises re-produced fluoroquinol injections, and only 6 enterprises have 6 market approvals.
2019, the domestic sales of fluorools amounted to 506.36 million yuan, of which Hunan Dongting Pharmaceuticals held the vast majority of market share, accounting for 94.66 percent.
before, according to netizens reported that because of the monopoly of raw materials, fluorool injections once several times soared, resulting in market shortages.
is now Shanghai Xudonghai Pu Pharmaceuticals fluorolinol injection declaration consistency evaluation was accepted, if successfully passed, in addition to competing for market advantages, in the existing collection gradually normal, may be expected to stabilize the market, to a certain extent to solve the market shortage.
.